💛 A quick favor, if you've got a second.
We're really happy that you chose to read one of our stories and sincerely hope you'll stick around to read more. We took our paywall down — for now — but that won't last forever, and when the gate goes back up, we'd love for you to already be on the inside.
It's free. So please enter your email here and don't forget to like and follow us on all of your favorite Social Media platforms!
Merck and Moderna revealed Wednesday that their investigational personalized mRNA cancer vaccine demonstrated efficacy in a substantial phase 3 clinical trial focused on high-risk melanoma patients. The announcement marks a significant milestone for the immunotherapy approach combining both companies’ expertise in vaccine development and oncology.
The personalized vaccine platform works by instructing patients’ immune systems to recognize and attack cancer cells specific to their tumors. The late-stage trial evaluated whether this approach could improve survival outcomes and reduce recurrence rates among melanoma patients at elevated risk of disease progression.
Results from the trial indicate the vaccine succeeded in extending survival duration for participating patients, though specific efficacy percentages and additional clinical data were not detailed in the companies’ initial announcement. The collaboration represents a broader industry shift toward tailored cancer immunotherapies designed around individual tumor genetics.
More Stories
Five Americans, Including Telemundo Executive, Killed in Kenya Helicopter Crash
Majority of Young Adults View AI with Skepticism Over Optimism, Pew Survey Finds
Doctors Warn That Coffee May Reduce Effectiveness of Oral Weight-Loss Medication Wegovy